XML 51 R38.htm IDEA: XBRL DOCUMENT v3.3.1.900
Summary of Significant Accounting Policies (Details Textual)
 1 Months Ended 12 Months Ended
Jan. 31, 2016
shares
Jan. 31, 2010
USD ($)
right
Dec. 31, 2015
USD ($)
segment
shares
Dec. 31, 2014
USD ($)
segment
shares
Dec. 31, 2013
USD ($)
shares
Aug. 31, 2014
USD ($)
Basis of Presentation [Line Items]            
Common shares excluded from computation | shares     3,300,000 5,100,000 800,000  
Maturity period of cash and cash equivalents, maximum     3 months      
Reserve for obsolete inventory     $ 0 $ 0    
Accounts receivable outstanding considered past due after period, minimum     30 days      
Accounts receivable outstanding considered past due after period, maximum     90 days      
Allowance for doubtful accounts     $ 0 0    
Definite lived intangibles, useful life     20 years      
Amortization expense     $ 2,400,000 2,400,000 $ 2,400,000  
Estimated amortization expense [Abstract]            
Amortization expense, 2016     2,400,000      
Amortization expense, 2017     2,400,000      
Amortization expense, 2018     2,400,000      
Amortization expense, 2019     2,400,000      
Amortization expense, 2020     2,400,000      
Amortization expense, 2021     2,400,000      
Depreciation expense     $ 200,000 $ 300,000 300,000  
Restocking fee (percent)     20.00%      
Milestone payment received     $ 0      
Share-based Compensation [Abstract]            
Number of reportable segments | segment     1 2    
Payments to CVR holders     $ 6,740,000 $ 3,493,000 989,000  
Other current liabilities     8,000 1,063,000    
Long-term deferred income taxes       2,792,000    
Impairment of Intangible Assets, Finite-lived     $ 0 0 0  
Stock Options | 2002 Stock Incentive Plan            
Share-based Compensation [Abstract]            
Award expiration period     10 years      
Stock Options | Vest 1/8 on the six month anniversary of the date of grant | 2002 Stock Incentive Plan            
Share-based Compensation [Abstract]            
Award vesting period     6 months      
Award vesting right percentage     12.50%      
Stock Options | Vest 1/48 each month for forty-two months | 2002 Stock Incentive Plan            
Share-based Compensation [Abstract]            
Award vesting period     42 months      
Award vesting right percentage     2.08%      
Director | 2002 Stock Incentive Plan            
Share-based Compensation [Abstract]            
Award vesting period     1 year      
Minimum            
Estimated amortization expense [Abstract]            
Sales/revenues from partners reporting period     30 days      
Maximum            
Estimated amortization expense [Abstract]            
Sales/revenues from partners reporting period     60 days      
CyDex            
Estimated amortization expense [Abstract]            
Fair value of contingent liability     $ 9,500,000 11,500,000    
Contingent liability change in amount     3,800,000 5,700,000 (600,000)  
Contingent liability, cash payment     5,800,000 3,500,000 1,000,000  
Metabasis Therapeutics            
Estimated amortization expense [Abstract]            
Fair value of contingent liability   $ 9,100,000 4,000,000 3,700,000    
Contingent liability change in amount     1,200,000 (500,000) 4,200,000  
Number of contingent value rights | right   4        
Number of contingent value rights per series of contingent value rights | right   1        
Number of series of contingent value rights issued per share | right   4        
Entitlement to cash payments (duration)   6 months        
Share-based Compensation [Abstract]            
Payments to CVR holders     900,000 0 0  
2019 Convertible Senior Notes            
Share-based Compensation [Abstract]            
Principal amount outstanding     245,000,000 245,000,000    
2019 Convertible Senior Notes | Senior Notes            
Share-based Compensation [Abstract]            
Principal amount outstanding           $ 245,000,000.0
Interest on debt instrument (percent)           0.75%
Omthera Pharmaceuticals            
Estimated amortization expense [Abstract]            
Revenue recognition, milestone method     1,000,000      
Proceeds from collaborators       500,000    
Omthera Pharmaceuticals | Collaborative Arrangement, Product            
Estimated amortization expense [Abstract]            
Revenue recognition, milestone method     100,000 400,000    
Inventories            
Basis of Presentation [Line Items]            
Purchase commitment     12,300,000      
IPR&D            
Estimated amortization expense [Abstract]            
Impairment charge     $ 0 0 $ 480,000.00  
New Accounting Pronouncement, Early Adoption, Effect            
Share-based Compensation [Abstract]            
Other current liabilities       (300,000)    
Long-term deferred income taxes       $ 300,000    
Subsequent Event | OMT, Inc.            
Share-based Compensation [Abstract]            
Shares issued for acquisition (shares) | shares 793,594